Efficacy and Safety of Ginkgo Biloba Pills for Coronary Heart Disease with Impaired Glucose Regulation: Study Protocol for a Series of N-of-1 Randomized, Double-Blind, Placebo-Controlled Trials

Mingyue Sun, Lulu Chai, Fang Lu, Yang Zhao, Qingna Li, Boya Cui, Rui Gao, Yue Liu, Mingyue Sun, Lulu Chai, Fang Lu, Yang Zhao, Qingna Li, Boya Cui, Rui Gao, Yue Liu

Abstract

Background: Coronary heart disease has become a serious challenge to China with its high prevalence and mortality. The impaired glucose regulation is prevalent in patients with cardiovascular disease. However, there are few drugs that interfere early with impaired glucose regulation. Ginkgo biloba extract not only is a commonly used drug for cardiovascular diseases, but also has a significant effect in reducing blood sugar. Therefore, this study used a single-case randomized controlled trial to explore the efficacy of Ginkgo biloba pills in the treatment of coronary heart disease patients with impaired glucose regulation.

Methods/design: This is a randomized, double-blind, placebo-controlled, three-period crossover trial for a single subject. A total of 12 subjects will be recruited in this trial. The trial is divided into three cycles, and one cycle has two treatment periods. Ginkgo biloba pills and placebo will be randomized during the treatment period. The test period will last for 58 weeks and subjects will take 48 weeks. Subjects will be selected by the researcher strictly in accordance with the inclusion and exclusion criteria.

Discussion: Ginkgo biloba preparations are widely used in cardiovascular diseases both at home and abroad due to their definite curative effect, few side effects, various dosage forms, and convenient and safe use. Diabetes mellitus is a high-risk factor for the occurrence of cardiovascular disease. Therefore, it is of great significance to control the impaired glucose regulation and slow down the development of diabetes and reduce the incidence and mortality of cardiovascular diseases. This trial is registered with ClinicalTrials.gov (ID: NCT03483779).

Figures

Figure 1
Figure 1
Flow of participants through the study.

References

    1. Collaborators M C O D. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, 2015, 385(9963):117-171.
    1. Bartnik M. The prevalence of abnormal glucose regulation in patients with coronary artery disease across EuropeThe Euro Heart Survey on diabetes and the heart. European Heart Journal. 2004;25(21):1880–1890. doi: 10.1016/j.ehj.2004.07.027.
    1. Santaguida P. L., Balion C., Hunt D., et al. Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. Evidence report/technology assessment (Summary). 2005;(128):1–11.
    1. Lu Y. Comparison of the effect of pre-diabetes lifestyle intervention and drug intervention. Zheng zhouUniversity; 2010.
    1. Herman W. H., Pan Q., Edelstein S. L., et al. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017;40(12):1668–1677. doi: 10.2337/dc17-1116.
    1. National Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science and Technology Press; 2010.
    1. Wang G.-X., Cao F.-L., Chen J. Progress in researches on the pharmaceutical mechanism and clinical application of Ginkgo Biloba extract on various kinds of diseases. Chinese Journal of Integrative Medicine. 2006;12(3):234–239. doi: 10.1007/BF02836532.
    1. Qiqi X., Wei L., Yang L., et al. Ginkgo biloba preparations and diabetes treatment: Mechanism of action and clinical application. Chinese Journal of Chinese Materia Medica. 2014;39(23):4509–4515.
    1. Ren M., Yang S., Li J., Hu Y., Ren Z., Ren S. Ginkgo biloba L. extract enhances the effectiveness of syngeneic bone marrow mesenchymal stem cells in lowering blood glucose levels and reversing oxidative stress. Endocrine Journal. 2013;43(2):360–369. doi: 10.1007/s12020-012-9745-5.
    1. Liang LiY B. Antihyperglycemic effect of Ginkgo biloba extract in streptozotocin-induced diabetes in rat. BioMed Research International. 2013
    1. Genfu P. Hu Dongda.Effects of Preparation of Ginkgo-biloba Leaves on the Coronary Heart Disease Patients with Blood Glucose, Serum Insulin and Lipids. Chinese Journal of Modern Applied Pharmacy. 2009;26(7):604–606.
    1. Chunyan L., Zhang Z., Qiuyan Y. The effects of EGb761 on islet function in db/db mice. Military Medical Journal of Southeast China. 2013;15(4):325–328.
    1. Yue LIU., Yan-fei LIU., Jin-fan TIAN. Cardiovascular Protection Mechanism of Extract of Ginkgo Biloba on the Rat Model of Type 2 Diabetes af-ter Myocardial Infarction. Vol. 37. 1100-1104: No.9; 2017.
    1. Jiang L. I., ZHAI Jing b. o., SHANG Hong c., Kehu4 Y., TIAN hui J., Jing C. Level of evidence and reporting standard in N-of-1 tria. Chinese Journal of Evidence-Based Medicine. 2017;17(05):612–615.
    1. Guyatt G. H., Haynes B., Jaeschke R. Z. The philosophy of evidence-based users guides to the medical literature. Chicago: AMA Press; 2002.
    1. Shamseer L., Sampson M., Bukutu C., et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration. BMJ. 2015;350(may14 15):h1793–h1793. doi: 10.1136/bmj.h1793.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere